Related Experiment Video

Updated: Feb 2, 2026

Virtual Reality Tools for Assessing Unilateral Spatial Neglect: A Novel Opportunity for Data Collection
07:04

Virtual Reality Tools for Assessing Unilateral Spatial Neglect: A Novel Opportunity for Data Collection

Published on: March 10, 2021

4.6K

Spironolactone in the treatment of hypertension: a neglected molecule

Jiří Veselý

    Vnitrni Lekarstvi
    |November 17, 2018
    PubMed

    Insights

    Spironolactone effectively lowers blood pressure and is crucial for treating resistant hypertension and heart failure. Recent studies confirm its benefits, solidifying its role in current medical guidelines.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Nephrology

    Background:

    • Spironolactone, a mineralocorticoid receptor antagonist, has been used for hypertension for over 50 years.
    • It is not a first-line treatment for primary hyperaldosteronism due to limited morbidity and mortality data.
    • Spironolactone holds a significant role in managing resistant hypertension.

    Purpose of the Study:

    • To review the evidence supporting spironolactone's role in hypertension, resistant hypertension, and heart failure.
    • To evaluate the impact of recent randomized studies on spironolactone's clinical application.
    • To assess spironolactone's place in current treatment guidelines.

    Main Methods:

    • Review of uncontrolled trials and randomized studies (ASPIRANT, PATHWAY-2) on spironolactone's antihypertensive effects.
    • Analysis of morbidity and mortality data in heart failure patients.
    • Examination of current clinical practice guidelines.

    Main Results:

    • Spironolactone demonstrates significant blood pressure lowering effects, especially in combination therapy.
    • Randomized studies confirm its superior antihypertensive efficacy compared to placebo and other agents.
    • Spironolactone reduces morbidity and mortality in heart failure with reduced ejection fraction and morbidity in heart failure with preserved ejection fraction.

    Conclusions:

    • Spironolactone is integral to managing resistant hypertension, primary hyperaldosteronism, and heart failure with reduced ejection fraction.
    • Clinical evidence supports its established role in current hypertension and heart failure guidelines.
    • Its benefits extend to patients with varying ejection fractions in heart failure management.

    More Related Videos

    Laser-Induced Chronic Ocular Hypertension Model on SD Rats06:34

    Laser-Induced Chronic Ocular Hypertension Model on SD Rats

    Published on: December 4, 2007

    11.8K
    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

    Published on: May 26, 2022

    4.1K

    Related Concept Videos

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    605
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
    467
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    509
    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

    Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
    Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
    619
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    534
    Hypertension I: Introduction01:28

    Hypertension I: Introduction

    Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
    879